Acetylcholinesterase inhibitors for Alzheimer's disease

Editorial

L Flicker. BMJ. 1999.

. 1999 Mar 6;318(7184):615-6.

doi: 10.1136/bmj.318.7184.615.

No abstract available

Comment in

Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
Selai CE, Trimble MR, Rossor MN, Harvey RJ. Selai CE, et al. BMJ. 1999 Sep 4;319(7210):641-2. BMJ. 1999. PMID: 10523095 No abstract available.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M. Rösler M, et al. BMJ. 1999 Mar 6;318(7184):633-8. doi: 10.1136/bmj.318.7184.633. BMJ. 1999. PMID: 10066203 Free PMC article. Clinical Trial.

1. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international, randomised controlled trial. BMJ. 1999;318:633–640. - PMC - PubMed
1. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986;315:1241–1245. - PubMed
1. Ames DJ, Bhathal PS, Davies BM, Fraser JR, Gibson PR, Roberts S. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust NZ J Med. 1990;20:193–195. - PubMed
1. Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S Cochrane Collaboration, editors. Cochrane Library. Issue 4. Oxford: Update Software; 1998. The efficacy of tacrine in Alzheimer’s disease.
1. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M.for the Dementia Trialists’ Collaboration. Cholinesterase inhibition for Alzheimer's disease: a meta-analysis of the tacrine trials JAMA 19982801777–1782. - PubMed